Role of amiloride in lithium induced kidney interstitial fibrosis

About this item

Title

Role of amiloride in lithium induced kidney interstitial fibrosis

Content partner

University of Otago

Collection

Otago University Research Archive

Description

Background Attenuating progressive fibrosis is fundamental to preventing chronic kidney disease and, ultimately, any accompanying end-stage kidney disease. Lithium treatment is associated with nephrogenic diabetes insipidus, changes to cellular morphology of the collecting duct and dilation of tubules. In the long term, lithium treatment causes irreversible chronic interstitial fibrosis. Nephrogenic diabetes insipidus is reversible when co-administration with amiloride, a sodium epithelial bl...

Read more

Format

Research paper

Research format

Scholarly text / Thesis

Thesis level

Doctoral

Date created

2022

Creator

Mehta, Paulomi

URL

https://hdl.handle.net/10523/12858

Related subjects

kidney / lithium / fibrosis

What is the copyright status of this item?

All Rights Reserved

This item is all rights reserved, which means you'll have to get permission from University of Otago before using it.

More Information

University of Otago has this to say about the rights status of this item:

All items in OUR Archive are provided for research purposes and private study and are protected by copyright with all rights reserved unless otherwise indicated.

What can I do with this item?

You must always check with University of Otago to confirm the specific terms of use, but this is our understanding:

Non-infringing use

NZ Copyright law does not prevent every use of a copyright work. You should consider what you can and cannot do with a copyright work.

No sharing

You may not copy and/or share this item with others without further permission. This includes posting it on your blog, using it in a presentation, or any other public use.

No modifying

You are not allowed to adapt or remix this item into any other works.

No commercial use

You may not use this item commercially.